Next-generation technology is a critical mid-step in dementia care

The past few years have seen outstanding progress in medication for previously incurable conditions. Most pertinent for me is the approval of lecanemab for use in the UK and elsewhere to slow the progress of early-stage Alzheimer’s disease. It isn’t a cure, but it brings us closer to dementia becoming a chronic condition managed with drugs.

But while lecanemab has been hailed as a game changer, it isn’t yet readily available and, in the meantime, 55 million people are living with dementia globally. By 2050, that will grow to 139 million. It is one of the biggest medical and…